FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis
Authors:
- 30 July 2016
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 48 (12) , 1492-1497
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinomaHepatology, 2013
- Cancer treatment cost in the United StatesCancer, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Hepatocellular Carcinoma: Epidemiology and Molecular CarcinogenesisGastroenterology, 2007
- Cost of Cancer Care: Issues and ImplicationsJournal of Clinical Oncology, 2007
- Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist, 2006
- Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumorsOncogene, 2006
- Hepatocellular Carcinoma: The Need for ProgressJournal of Clinical Oncology, 2005
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Systemic therapy for advanced hepatocellular carcinoma: a reviewEuropean Journal of Cancer, 2004